Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01157416 · ClinicalTrials.gov registry record · Phase 2
Effect of D-cycloserine on Treatment of Posttraumatic Stress Disorder (PTSD) in Youth
A Phase 2 study, sponsored by Tulane University School of Medicine.
- Completed
- Registry status
- Phase 2
- Development phase
- 33
- Enrollment target
NCT01157416: Completed Phase 2 study, sponsored by Tulane University School of Medicine.
NCT01157416 is a Phase 2 study that has completed, run by Tulane University School of Medicine. The registered enrollment target is 33 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (75% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01157416, a Phase 2 study, has completed, sponsored by Tulane University School of Medicine.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 33 participants
- Enrollment target
Study Summary
The purpose of this study is to show whether D-cycloserine in combination with cognitive behavioral therapy (CBT) is more effective than CBT plus placebo to reduce symptoms of posttraumatic stress disorder (PTSD) in 7-12 year old children.
Primary Outcome
The CPSS is a 17-item standardized, self-administered questionnaires with versions for both youths and caregivers. Items are scored on 0-3 scale. Minimum possible score is 0 and maximum is 51. Only the total score is used; there are no subscales. A higher score indicates greater symptom severity (worse).
Interventions
- DRUG Placebo pill
- BEHAVIORAL CBT
- DRUG D-cycloserine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2010-06 |
| Est. Completion | 2012-06 |
| Phase | Phase 2 |
What the finished NCT01157416 record still lists
NCT01157416 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 33 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (75% lower).
The record links to 0 conditions, and to 3 interventions - of which Placebo pill is the first listed.
NCT01157416 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01157416 about?
NCT01157416 is a clinical study titled "Effect of D-cycloserine on Treatment of Posttraumatic Stress Disorder (PTSD) in Youth". The purpose of this study is to show whether D-cycloserine in combination with cognitive behavioral therapy (CBT) is more effective than CBT plus placebo to reduce symptoms of posttraumatic stress disorder (PTSD) in 7-12 year old children.
What is the current status of trial NCT01157416?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 33 participants. The study started on 2010-06. Estimated completion is 2012-06.
What interventions are being tested in trial NCT01157416?
The interventions under investigation include: Placebo pill (DRUG), CBT (BEHAVIORAL), D-cycloserine (DRUG).
Who is sponsoring clinical trial NCT01157416?
This trial is sponsored by Tulane University School of Medicine, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01157416's enrollment target sits among peer trials
33 1553rd of 2000 higher than 438 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02861898 · 33 participants · Phase 1
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
- NCT04871607 · 33 participants · Phase 2
Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma
- NCT05071937 · 33 participants · Phase 2
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
- NCT05168618 · 33 participants · Phase 2
Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer, The AtezoCab Trial
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia